CURRENT STATUS OF CLINICAL TRIALS FOR ALZHEIMER’S DISEASE

A. Rodríguez-Alarcón, ME. Navarrete-Rouco, P. Acín, M. Ponce, M. Jorques, O. Ferrández-Quirante, M. Espona

1Hospital del Mar, Pharmacy Department, Barcelona, Spain.

Key words: amyloid plaques, Aβ amyloid peptide, Alzheimer disease

Abstract number: 4CPS-140
ATC code: N06 – Psychoanaleptics

Background
Alzheimer’s disease (AD) is a progressive neurodegenerative process caused by an accumulation of the Aβ amyloid peptide.

Objectives
The objective of this study is to describe clinical trials’ (CT) current status for AD in our hospital pharmacy service and to analyze the investigational drugs.

Material and methods
Observational descriptive retrospective study performed in a tertiary academic hospital from 1st January 2014 until 31st March 2019.

Data collected: total CT and total included patients, demographic data, total of CT classified by: CT status, phase, therapeutic target, administration route, CT with results and type of result.

Results
12 CT for AD were analyzed: 6 (50.0%) CT were in active and 3 (25.0%) CT had results, all of them were negative (3 (100%)).

<table>
<thead>
<tr>
<th>Demographic data</th>
<th>N=12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total patients included</td>
<td>59</td>
</tr>
<tr>
<td>Patients per CT, mean (rank)</td>
<td>5 (0-8)</td>
</tr>
<tr>
<td>Age (years), mean (Rank)</td>
<td>77.4 (71.5-84.7)</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>34 (57.6)</td>
</tr>
</tbody>
</table>

Conclusions
Most number of CT in active were in phase III. Only 25% CT had results and all of them were negative. Almost 60% CT has studied the oral administration, which stands out patient’s preferences. There are 5 therapeutic targets currently on study, however, more than 40% CT evaluate AP’s reduction.

Based on everything said above, should we rethink the basis of Alzheimer before continuing to develop clinical trials with the same therapeutic target?